- Home
- NTIP vs GDTC Comparison
NTIP vs GDTC Comparison
Compare NTIP & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- GDTC
- Stock Information
- Founded
- NTIP 1990
- GDTC 2018
- Country
- NTIP United States
- GDTC Singapore
- Employees
- NTIP N/A
- GDTC N/A
- Industry
- NTIP Multi-Sector Companies
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- GDTC Health Care
- Exchange
- NTIP Nasdaq
- GDTC Nasdaq
- Market Cap
- NTIP 32.0M
- GDTC 21.5M
- IPO Year
- NTIP 1998
- GDTC 2023
- Fundamental
- Price
- NTIP $1.56
- GDTC $2.18
- Analyst Decision
- NTIP
- GDTC Buy
- Analyst Count
- NTIP 0
- GDTC 1
- Target Price
- NTIP N/A
- GDTC $5.00
- AVG Volume (30 Days)
- NTIP 66.2K
- GDTC 13.2K
- Earning Date
- NTIP 10-23-2025
- GDTC 01-01-0001
- Dividend Yield
- NTIP 6.33%
- GDTC N/A
- EPS Growth
- NTIP N/A
- GDTC N/A
- EPS
- NTIP N/A
- GDTC N/A
- Revenue
- NTIP $150,000.00
- GDTC $368,838.00
- Revenue This Year
- NTIP N/A
- GDTC $5.37
- Revenue Next Year
- NTIP N/A
- GDTC N/A
- P/E Ratio
- NTIP N/A
- GDTC N/A
- Revenue Growth
- NTIP N/A
- GDTC N/A
- 52 Week Low
- NTIP $1.16
- GDTC $1.20
- 52 Week High
- NTIP $1.90
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- NTIP 53.49
- GDTC 63.22
- Support Level
- NTIP $1.56
- GDTC $1.82
- Resistance Level
- NTIP $1.63
- GDTC $2.27
- Average True Range (ATR)
- NTIP 0.08
- GDTC 0.09
- MACD
- NTIP -0.00
- GDTC 0.03
- Stochastic Oscillator
- NTIP 32.00
- GDTC 80.00
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.